| A nationwide survey of prescribing patterns for thrombolytic drugs in acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 2107535 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In November 1988, 164 hospitals enrolled in the Drug Surveillance Network participated in a nationwide survey of prescribing patterns for thrombolytic drugs for patients with an acute myocardial infarction. The results indicated that alteplase has made dramatic inroads, being used exclusively in 14.6% of the hospitals; in 64% of the hospitals both alteplase and streptokinase were on the formulary. Overall, however, only 17% of patients admitted with an acute myocardial infarction were treated with a thrombolytic, and use of these agents varied markedly across institutions. One of the reasons for this low figure may be the current maximum allowable time from onset of symptoms to administration of a thrombolytic. This time limit was less than 6 hours in the majority of hospitals in spite of recent evidence suggesting that these drugs may be effective up to 24 hours after onset of symptoms. The low and variable use of the agents for acute myocardial infarction suggests the need to identify patient- and physician-related obstacles so that overall attitudes and professional practice can be modified to reverse this trend. Given large number of institutions reporting the presence of formal, prospective, pharmacy-initiated monitoring programs, we suggest that clinical pharmacists will play a major role in implementing the necessary changes. |
| | |
Authors:
|
T H Grasela; J A Green |
Related Documents
:
|
10402105 - Gpiibiiia inhibitors as adjunctive therapy in acute myocardial infarction. 3315595 - Recent clinical developments in thrombolysis in acute myocardial infarction. 3142945 - Thrombolytic reperfusion of acute myocardial infarction: resolved and unresolved issues. 8694005 - Management of acute myocardial infarction: evaluating the past, practicing in the prese... 20122555 - Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk... 17022375 - Predictors of failure of endovascular therapy for peripheral arterial disease. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pharmacotherapy Volume: 10 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 1990 |
Date Detail:
|
Created Date: 1990-04-24 Completed Date: 1990-04-24 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 35-41 Citation Subset: IM |
Affiliation:
|
Center for Pharmacoepidemiology Research, School of Pharmacy, State University of New York, Buffalo 14260. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Demography Fibrinolytic Agents / therapeutic use* Humans Middle Aged Myocardial Infarction / drug therapy* Prospective Studies Questionnaires Streptokinase / therapeutic use Thrombolytic Therapy / utilization* Time Factors Tissue Plasminogen Activator / therapeutic use Urokinase-Type Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The roles of indoleglycerol phosphate and the TrpI protein in the expression of trpBA from Pseudomon...
Next Document: Chronic granulomatous disease of childhood: clinical, pathological, biochemical, molecular, and gene...